GentiBio
Aaron Deykin is an experienced healthcare executive and medical professional with a diverse background in clinical and research roles. As a Director on the Board of Directors at GentiBio, and serving as Chief Medical Officer and Head of Research and Development at Upstream Bio, Deykin has a strong leadership presence in the biotechnology sector. Previous positions at Biogen include Senior Vice President of Clinical Sciences and Vice President for Late Stage Clinical Development and Multiple Sclerosis Clinical Development. Deykin has also held significant academic roles, including Assistant Professor of Medicine at Harvard Medical School and various directorships at Brigham and Women's Hospital. Educationally, Deykin earned a Doctor of Medicine (MD) from Harvard Medical School and an AB in Psychology/Biology from Dartmouth College.
This person is not in the org chart
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.